NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above ...

Amid a cautious outlook, Biogen has presented new data at the Alzheimer’s Association International Conference (AAIC) 2025, demonstrating that investigational Leqembi 360 mg subcutaneous maintenance ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Similarly, BIIB has 37.14% upside from the recent share price of $124.99 if the average analyst target price of $171.41/share is reached, and analysts on average are expecting CTRA to reach a ...

(RTTNews) - Biogen Inc. (BIIB) said it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. In the next few years, Biogen ...

Biogen (BIIB) is down more than -2% to lead losers in the Nasdaq 100 after Truist Securities downgraded the stock to hold from buy.

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Biogen Inc. (NASDAQ: BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina ...